


Eupalinolide A

Chemical Properties

| | |
|-------------------|--|
| CAS No. : | 877822-40-7 |
| Formula: | C ₂₄ H ₃₀ O ₉ |
| Molecular Weight: | 462.49 |
| Storage: | Keep away from direct sunlight, Store at low temperature Powder: -20°C for 3 years In solvent: -80°C for 1 year <i>Actual storage temperature shall be subject to the COA.</i> |



Biological Description

| | |
|---------------|--|
| Description | Eupalinolide B is a natural product, and demonstrates potent cytotoxicity against A-549, BGC-823, SMMC-7721, and HL-60 tumour cell lines. |
| Targets(IC50) | HSP |
| In vitro | Eupalinolide B and A (EB and EA) from <i>E. lindleyanum</i> , and describe their actions as HSP-inducers. EA and EB both induced the expression of HSP70 in cells at concentrations that did not significantly affect cell viability. Treatment of cells with EA or EB activated heat shock factor 1 (HSF1), while the artificial suppression of HSF1 expression diminished the EA- or EB-mediated induction of HSP70 expression. Furthermore, EB inhibited the interaction between HSF1 and HSP90, which is known to inhibit the activity of HSF1. Suggest that EA and EB induce the expression of HSP70 via the activation of HSF1 by inhibiting the interaction between HSF1 and HSP90. EA and EB both induced the expression of HSP70 synergistically with other stressors. Furthermore, pre-treatment of cells with EA or EB suppressed melanin production and stressor-induced apoptosis. These effects were suppressed by the artificial suppression of HSP70 expression. In vivo, the percutaneous administration of EB induced the expression of HSP70 and suppressed UVB radiation-induced damage, inflammatory responses and melanin production in the skin.[1] |

Solubility Information

| | |
|---------------------|---|
| Solubility | DMSO: 240 mg/mL (518.93 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble) |
| In vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.32 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i> |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|-----------|------------|
| 1 mM | 2.1622 mL | 10.811 mL | 21.6221 mL |
| 5 mM | 0.4324 mL | 2.1622 mL | 4.3244 mL |
| 10 mM | 0.2162 mL | 1.0811 mL | 2.1622 mL |
| 50 mM | 0.0432 mL | 0.2162 mL | 0.4324 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Yamashita Y , Ikeda T , Matsuda M , et al. Purification and characterization of HSP-inducers from *Eupatorium lindleyanum*[J]. *Biochemical Pharmacology*, 2012, 83(7):909-922.

Zhang J , Zhao F , Yu X , et al. Pharmacokinetics of eupalinolide A, eupalinolide B and hyperoside from *Eupatorium lindleyanum* in rats by LC/MS/MS[J]. *Journal of Chromatography B*, 2015, 995-996:1-7.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481